Search

Hubert B Josien

from Jersey City, NJ
Age ~58
Get Report
Connected to:
Marvin H Josif, 58Harry Josifidis, 69Dragana Josipovic, 33Magdalena Josipovic, 43Tanja Josipovic, 27Frederick M Josker, 41Huljev Josko, 59Jimmy L Josko, 73Jules Joskow, 102Serge P Joskow, 71

Hubert Josien Phones & Addresses

  • 293 Pavonia Ave, Jersey City, NJ 07302 (201) 659-1741
  • 317 Monroe St, Hoboken, NJ 07030 (201) 659-6662
  • 317 Monroe St #3, Hoboken, NJ 07030 (201) 659-6662
  • Sterling, VA
  • Gibson City, IL
  • Pittsburgh, PA

Work

Company: Merck Nov 2009 to Dec 11, 2016 Position: Principal scientist

Education

Degree: Doctorates School / High School: University of Pittsburgh 1994 to 1996

Skills

Medicinal Chemistry • Chemistry New Modalities • Drug Design • In Silico Tools • Cross Functional Team Leadership

Industries

Pharmaceuticals

Resumes

Resumes

Hubert Josien Photo 1

Principal Scientist

View page
Location:
293 Pavonia Ave, Jersey City, NJ 07302
Industry:
Pharmaceuticals
Work:
Merck Nov 2009 - Dec 11, 2016
Principal Scientist
Schering-Plough Research Institute Dec 1996 - Nov 2009
Principal Scientist
Education:
University of Pittsburgh 1994 - 1996
Doctorates
Skills:
Medicinal Chemistry
Chemistry New Modalities
Drug Design
In Silico Tools
Cross Functional Team Leadership

Publications

Us Patents

Piperidine Derivatives Useful As Ccr5 Antagonists

View page
US Patent:
6387930, May 14, 2002
Filed:
May 1, 2000
Appl. No.:
09/562815
Inventors:
Bahige M. Baroudy - Westfield NJ
John W. Clader - Cranford NJ
Hubert B. Josien - Jersey City NJ
Stuart W. McCombie - Caldwell NJ
Brian A. McKittrick - Bloomfield NJ
Michael W. Miller - Westfield NJ
Bernard R. Neustadt - West Orange NJ
Anandan Palani - Kenilworth NJ
Ruo Steensma - Weehawken NJ
Jayaram R. Tagat - Westfield NJ
Susan F. Vice - Mountainside NJ
Mark A. Laughlin - Edison NJ
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
C07D40104
US Classification:
514316, 546186, 546187, 546188, 546191, 544242, 544336
Abstract:
The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein X is âC(R ) â, âC(R )(R )â, âC(O)â, âOâ, âNHâ, âN(alkyl)â, R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R is H, alkyl or alkenyl; R is optionally substituted phenyl, phenylalkyl, heteroaryl or heteroarylalkyl, naphthyl, fluorenyl or diphenylmethyl; R is optionally substituted phenyl, heteroaryl or naphthyl; R is H, alkyl, fluoro-alkyl, cyclopropylmethyl, âCH CH OH, âCH CH âO-alkyl, âCH C(O)âO-alkyl, âCH C(O)NH , âCH C(O)âNHalkyl or âCH C(O)âN(alkyl) ; R is optionally substituted phenyl, heteroaryl or naphthyl, cycloalkyl, cycloalkylalkyl or alkoxyalkyl; and R , R , R , R and R are hydrogen or alkyl for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.

Piperazine Derivatives Useful As Ccr5 Antagonists

View page
US Patent:
6391865, May 21, 2002
Filed:
May 1, 2000
Appl. No.:
09/562814
Inventors:
Bahige M. Baroudy - Westfield NJ
John W. Clader - Cranford NJ
Hubert B. Josien - Jersey City NJ
Stuart W. McCombie - Caldwell NJ
Brian A. McKittrick - Bloomfield NJ
Michael W. Miller - Westfield NJ
Bernard R. Neustadt - West Orange NJ
Anandan Palani - Kenilworth NJ
Elizabeth M. Smith - Verona NJ
Ruo Steensma - Weehawken NJ
Jayaram R. Tagat - Westfield NJ
Susan F. Vice - Mountainside NJ
Eric Gilbert - Scotch Plains NJ
Marc A. Labroli - Mount Laurel NJ
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
A01N 5500
US Classification:
514 63, 514 64, 51425211, 51425218, 51425301, 5142531, 51425311, 51425309, 544229, 544295, 544360, 544364
Abstract:
The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R is hydrogen or alkyl; R is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl; R is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R , R and R are hydrogen or alkyl; R is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.

Camptothecin Analogs And Methods Of Preparation Thereof

View page
US Patent:
6455699, Sep 24, 2002
Filed:
Aug 7, 2000
Appl. No.:
09/633561
Inventors:
Dennis P. Curran - Pittsburgh PA
Hubert Josien - Jersey City NJ
Bom David - Pittsburgh PA
Assignee:
University of Pittsburgh - Pittsburgh PA
International Classification:
C07F 708
US Classification:
546 14
Abstract:
The present invention provides generally a compound having the following general formula (1): wherein R and R are independently the same or different and are hydrogen, an alkyl group, an alkenyl group, a benzyl group, an alkynyl group, an alkoxyl group, an aryloxy group, an acyloxy group, âOC(O)OR , wherein R is an alkyl group, a carbamoyloxy group, a halogen, a hydroxyl group, a nitro group, a cyano group, an azido group, a formyl group, a hydrazino group, an acyl group, an amino group, âSR , wherein, R is hydrogen, an acyl group, an alkyl group, or an aryl group, or R and R together form a group of the formula âO(CH ) Oâ wherein n represents the integer 1 or 2; R is H, F, a halogen atom, a nitro group, an amino group, a hydroxyl group, or a cyano group; or R and R together form a group of the formula âO(CH ) Oâ wherein n represents the integer 1 or 2; R is H, F, a C alkyl group, a C alkenyl group, a C alkynyl group, or a C alkoxyl group; R is a C alkyl group, or a propargyl group; and R , R and R are independently a C alkyl group, a C alkenyl group, a C alkynyl group, an aryl group or a â(CH ) R group, wherein N is an integer within the range of 1 through 10 and R is a hydroxyl group, alkoxy group, an amino group, an alkylamino group, a dialkylamino group, a halogen atom, a cyano group or a nitro group; and pharmaceutically acceptable salts thereof.

Piperidine Derivatives Useful As Ccr5 Antagonists

View page
US Patent:
6602885, Aug 5, 2003
Filed:
Nov 8, 2001
Appl. No.:
10/010481
Inventors:
Bahige M. Baroudy - Westfield NJ
John W. Clader - Cranford NJ
Hubert B. Josien - Jersey City NJ
Stuart W. McCombie - Caldwell NJ
Brian A. McKittrick - Bloomfield NJ
Michael W. Miller - Westfield NJ
Bernard R. Neustadt - West Orange NJ
Anandan Palani - Kenilworth NJ
Ruo Steensma - Weehawken NJ
Jayaram R. Tagat - Westfield NJ
Susan F. Vice - Mountainside NJ
Mark A. Laughlin - Edison NJ
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
A61K 314545
US Classification:
514316, 546186, 546187, 546188, 546191, 544542, 544336
Abstract:
The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R is H, alkyl or alkenyl; R is optionally substituted phenyl, phenylalkyl, heteroaryl or heteroarylalkyl, naphthyl, fluorenyl or diphenylmethyl; R is optionally substituted phenyl, heteroaryl or naphthyl; R is H, alkyl, fluoro-alkyl, cyclopropylmethyl, âCH CH OH, âCH CH âO-alkyl, âCH C(O)âO-alkyl, âCH C(O)NH , âCH C(O)âNHalkyl or âCH C(O)âN(alkyl) ; R is optionally substituted phenyl, heteroaryl or naphthyl, cycloalkyl, cycloalkylalkyl or alkoxyalkyl; and R , R , R , R and R are hydrogen or alkyl for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.

Intermediates In The Synthesis Of Camptothecin And Related Compounds And Synthesis Thereof

View page
US Patent:
6620937, Sep 16, 2003
Filed:
Mar 23, 2001
Appl. No.:
09/815459
Inventors:
Dennis P. Curran - Pittsburgh PA
Hubert Josien - Hoboken NJ
Sung Bo Ko - Taejon, KR
Assignee:
University of Pittsburgh - Pittsburgh PA
International Classification:
C07D491052
US Classification:
546116, 546 48, 546 70, 546300, 546302, 546 41, 546 14, 544342, 544343, 544361, 544362
Abstract:
The present invention provides a short, convergent total synthesis of camptothecin and related compounds which consists of a novel 4+1 radical annulation. The present invention also provides novel chemical intermediates for such 4+1 radical annulations.

Gamma Secretase Inhibitors

View page
US Patent:
6683091, Jan 27, 2004
Filed:
Aug 1, 2002
Appl. No.:
10/210829
Inventors:
Theodoros Asberom - West Orange NJ
Henry S. Guzik - Brooklyn NY
Hubert B. Josien - Hoboken NJ
Dmitri A Pissarnitski - Scotch Plains NJ
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
C07D21560
US Classification:
514312, 546153
Abstract:
This invention discloses novel gamma secretase inhibitors of the formula: wherein: R is a substituted aryl or substituted heteroaryl group; R is an R group, alkyl, âX(CO)Y, â(CR ) X(CO)Y; each R is independently H or alkyl; X is âOâ, âNH, or âN-alkyl; and Y is âNR R , or âN(R )(CH ) NR R. Also disclosed is a method of treating Alzheimers Disease.

Piperazine Derivatives Useful As Ccr5 Antagonists

View page
US Patent:
6689765, Feb 10, 2004
Filed:
Jan 30, 2002
Appl. No.:
10/061011
Inventors:
Bahige M. Baroudy - Westfield NJ
John W. Clader - Cranford NJ
Hubert B. Josien - Jersey City NJ
Stuart W. McCombie - Caldwell NJ
Brian A. McKittrick - Bloomfield NJ
Michael W. Miller - Westfield NJ
Bernard R. Neustadt - West Orange NJ
Anandan Palani - Kenilworth NJ
Elizabeth M. Smith - Verona NJ
Ruo Steensma - Weehawken NJ
Jayaram R. Tagat - Westfield NJ
Susan F. Vice - Mountainside NJ
Mark A. Laughlin - Edison NJ
Eric Gilbert - Scotch Plains NJ
Marc A. Labroli - Mount Laurel NJ
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
A61K 31695
US Classification:
514 63, 514 64, 51425212, 51425213, 51425219, 51425301, 5142531, 51425311, 514 2, 514 42, 514 43, 514 45, 514 49, 514220, 514262, 514263
Abstract:
The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R is hydrogen or alkyl; R is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl; R is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R , R and R are hydrogen or alkyl; R is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v, host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.

Camptothecin Analogs And Methods Of Preparation Thereof

View page
US Patent:
6743917, Jun 1, 2004
Filed:
Apr 29, 2002
Appl. No.:
10/134781
Inventors:
Dennis P. Curran - Pittsburgh PA
Hubert Josien - Jersey City NJ
David Bom - Pittsburgh PA
Thomas G. Burke - Lexington KY
Assignee:
University of Pittsburgh - Pittsburgh PA
International Classification:
C07D40514
US Classification:
546 14
Abstract:
A compound and a method of synthesizing a compound having the following general formula (1): wherein R and R are independently the same or different and are hydrogen, an alkyl group, an alkenyl group, a benzyl group, an alkynyl group, an alkoxy group, an aryloxy group, an acyloxy group, âOC(O)OR , wherein R is an alkyl group, a carbamoyloxy group, a halogen, a hydroxy group, a nitro group, a cyano group, an azido group, a formyl group, a hydrazino group, an acyl group, an amino group, âSR , wherein, R is hydrogen, an acyl group, an alkyl group, or an aryl group, or R and R together form a group of the formula âO(CH ) Oâ wherein n represents the integer 1 or 2; R is H, F, a halogen atom, a nitro group, an amino group, a hydroxy group, or a cyano group; or R and R together form a group of the formula âO(CH ) Oâ wherein n represents the integer 1 or 2; R is H, a trialkylsilyl group, F, a C alkyl group, a C alkenyl group, a C alkynyl group, or a C alkoxy group; R is a C alkyl group, an allyl group, a benzyl group or a propargyl group; and R , R and R are independently a C alkyl group, a C alkenyl group, a C alkynyl group, an aryl group or a â(CH ) R group, wherein N is an integer within the range of 1 through 10 and R is a hydroxy group, alkoxy group, an amino group, an alkylamino group, a dialkylamino group, a halogen atom, a cyano group or a nitro group; and R is an alkylene group or an alkenylene group, and pharmaceutically acceptable salts thereof.
Control profile
Hubert B Josien from Jersey City, NJ, age ~58 Get Report